eligibility_summary
Eligible: age 3–70 with relapsed/refractory NK/T lymphoma, CD7+, ≥5% marrow blasts, ECOG 0–2, LVEF ≥50%, CrCl ≥60, ALT/AST <3×ULN, bilirubin <1.5×ULN, O2 sat ≥92%, survival >3 mo, consent. Exclude: marrow-failure syndromes, isolated extramedullary disease, cardiac issues, CNS3 or neuro disorders, other malignancy, primary immunodeficiency, uncontrolled infections, recent anticancer therapy, HIV/HBV/HCV/syphilis, systemic steroids.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06732492 tests RD13-02, a CD7-directed CAR-T cell therapy (genetically engineered cellular immunotherapy) delivered intravenously to patients with relapsed/refractory CD7-positive NK/T-cell malignancies. Mechanism: T cells are modified to express a chimeric antigen receptor that binds CD7, triggering TCR-independent activation and targeted cytotoxic killing (perforin/granzyme and cytokine-mediated) of CD7-expressing malignant T/NK cells. Targets: CD7 antigen on T- and NK-cell lineages, activation of CAR signaling and immune effector pathways. Primary aim: safety and PK.